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Biomarkers will be essential in identifying subjects with prodromal Alzheimer’s disease, in 
stratifying people for treatment trials and for analysing data from such trials.  In their position 
paper “A strategic research agenda to the biomarker-based diagnosis of prodromal Alzheimer’s 
disease”, Boccardi et al. 1 set out the evidence for Alzheimer’s disease (AD) biomarkers using 
a framework developed in oncology.  This comprehensive review of imaging and CSF 
biomarkers draws attention to the lack of common standards and clinical validation across 
different health systems and the subsequent impact on diagnosis and prognosis. Unless 
addressed this will limit  the ability of the community to conduct appropriately powered clinical 
trials.  They comment on the potential power to be gained from integrating multiple biomarkers 
- this power could be further augmented by including genetic risk scores.   
 
The successful identification of dozens of risk loci associated with AD has changed our view 
of its pathobiology, but so far the impact on diagnosis, therapies or prevention is small. 
Genomic profiling, using polygenic risk scores – summing the genetic risks over 1000s of DNA 
variants associated with disease - is a promising tool for prediction of risk of future progression 
to AD in premanifest or early symptomatic individuals, as the genetic risk remains unchanged 
throughout an individual’s lifetime. The area under the receiver operator characteristic curve 
(AUC) is the most widely accepted test of prediction accuracy for classifying diseased and 
unaffected individuals (see Box 1). The AUC statistic of a genomic profile for any disease has 
an upper limit dictated by heritability and disease prevalence2. High prediction accuracy 
through genomic profiling can be achieved for diseases with high heritability and low 
prevalence, though late onset AD is neither. Nevertheless prediction is possible in AD. The 
maximum AUC statistic prediction accuracy by genetic profiling in clinical samples is 
estimated at 82% (for a lifetime AD prevalence 2%), compared with 68.8% based upon APOE-
e4 and APOE-e2 alleles alone3,4. The most recent study by Desikan et al, 20175 provided an 
independent validation of the polygenic risk score approach, using survival analysis modelling, 
to integrate AD risk variants for quantifying age of onset. Both studies demonstrated a strong 
genetic component that can be useful in predicting and modifying AD risk and might be 
usefully added to the panels of imaging and CSF biomarkers to augment their predictive 
abilities. 
 
The expectation is that in AD, as in cancer, comprehensive genomic profiling will be critical 
in choosing targeted therapies based on the patient’s unique risk profile. Whilst the polygenic 
risk scoring outlined above is a promising approach, genomic profiling for AD is still in its 
infancy, and integration with other emerging biomarkers would aid diagnostic power6. The 
clinical value of current AD genomic profiling in matching patients to targeted therapies needs 
to be investigated: one way of assessing the potential of this approach would be to examine 
performance in stratifying response in previous clinical trials.  
 
A caveat to this is that genetic information can be generated at any point and a clear 
distinction needs to be made between the use of genetics in exploring disease mechanisms 
and powering treatment trials versus estimating risk of future disease in individuals who are 
currently well before the age of disease risk. Genetic testing for Mendelian diseases in at risk 
subjects has been available for many years but in diseases with few interventions is often not 
taken up. In Huntington’s disease only 10-20% of the at risk population take up testing to 
confirm their genetic risk7.  Even in diseases with available interventions such as inherited 
forms of breast and colon cancer, such testing is not always taken up8,9.  Care must be 
exercised in the presentation of genetics to predict who will get disease.  In any individual we 
cannot currently give a precise risk estimate of AD susceptibility and shifting of diagnostic 
boundaries to include the currently well raises other ethical dilemmas10.  Even if it were 
theoretically possible people might well choose not to know their status for a late-life disease 
such as AD.  Much work in the presentation of such risks has been carried out by clinicians 
and genetic counsellors in inherited diseases, guided by their patient populations, and this 
valuable experience can guide the use of genetic data in common diseases with a heritable 
component. In addition there are some future challenges for which we should prepare: the 
advent of clinical trials for premanifest at risk people and new effective treatments will 
inevitably bring people forward for genomic risk prediction.  These issues require serious 
consideration by scientists and clinicians working in AD, particularly when presenting 
research findings to the public.  
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Box 1  
Genomic profile is often understood as individual’s unique measure which combines the 
effects of many associated genetic variants to predict risk of disease. 
The polygenic score for an individual is based upon aggregation of AD risk alleles which this 
individual carries. Since the contribution of genetic variants to the disease risk is different, 
the individual risk score is calculated as sum of risk genetic variants weighted by their AD-
related effect sizes. The genetic risk variants comprising the polygenic score, are pre-selected 
from large and powerful AD genome-wide studies, and capture those which are most 
associated with the disease. 
 
The ability of the polygenic score distribution to distinguish those with disease from 
cognitively normal individuals is assessed using logistic regression analysis. As a result of the 
logistic regression analysis the prediction probability (value between 0 and 1) is provided for 
each individual. The quality of the prediction can be assessed looking at the proportions of 
correctly predicted cases and controls (sensitivity and specificity) in this sample. The AUC 
measure combines the sensitivity and specificity into one single metric, and reflects the 
overall prediction accuracy of the polygenic risk score based classification. 
 
 
 
 
 
 
 
 
